Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00609141
Other study ID # NCI-2009-00363
Secondary ID NCI-2009-00363CO
Status Completed
Phase Phase 1
First received February 2, 2008
Last updated June 18, 2014
Start date January 2008

Study information

Verified date June 2014
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I clinical trial is studying the side effects and best dose of IMC-A12 in treating young patients with relapsed or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor or other solid tumors. Monoclonal antibodies, such as IMC-A12, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.


Description:

PRIMARY OBJECTIVES:

I. To estimate the maximum tolerated dose (MTD) or recommended phase II dose of IMC-A12 (cixutumumab) in children with relapsed or refractory solid tumors using a limited dose-escalation strategy.

II. To define and describe the toxicities of this drug in children with relapsed or refractory solid tumors.

III. To characterize the pharmacokinetics of this drug in children with relapsed or refractory solid tumors.

SECONDARY OBJECTIVES:

I. To preliminarily define the antitumor activity of this drug in children with relapsed or refractory solid tumors within the confines of a phase I study.

II. To obtain initial phase II efficacy data on the antitumor activity of this drug in children with Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET).

III. To examine change in IGF-IR and insulin receptor (IR) levels and IGF-IR and IR activation in lymphocytes as biomarkers of IMC-A12 action and specificity.

IV. To evaluate the effect of this drug on circulating levels of proteins involved in linear growth and glucose homeostasis, including IGF-I, IGF-II, IGF-BP3, growth hormone, insulin, and C-peptide.

V. To develop exploratory data concerning biomarkers of activity.

OUTLINE: This is a dose-escalation study.

Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for up to 2 years in the absence of unacceptable toxicity or disease progression.

Patients undergo blood sample collection periodically for pharmacokinetic, immunogenicity, and other correlative studies. Samples are analyzed for serum levels of IGF-I, IGF-II, IGF-BP3, growth hormone, insulin, and C-peptide; trough concentrations and PK sampling; and biomarkers, including IGF-IR expression and phosphorylation and insulin receptor expression and phosphorylation via immunoprecipitation and Western immunoblotting. Tumor tissue samples from patients with Ewing sarcoma/peripheral PNET are banked for future research.

After completion of study treatment, patients are followed at 30 days.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date
Est. primary completion date September 2009
Accepts healthy volunteers No
Gender Both
Age group 1 Year to 21 Years
Eligibility Inclusion Criteria:

- Histologically confirmed solid tumor

- Relapsed or refractory disease

- No central nervous system (CNS) tumor or lymphoma

- Histological confirmation may have been made at original diagnosis or at relapse

- Current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life

- Measurable or evaluable disease

- Patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET) must have tissue blocks or slides available

- Study chair must be notified if tissue blocks or slides are not available

- Karnofsky performance status (PS) = 50% (patients > 10 years of age) and Lansky (PS) = 50% (patients = 10 years of age)

- Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score

- Creatinine clearance or radioisotope GFR = 70 mL/min OR serum creatinine based on age/gender as follows:

- 1 to < 2 years (males and females 0.6 mg/dL)

- 2 to < 6 years (males and females 0.8 mg/dL)

- 6 to < 10 years (males and females 1.0 mg/dL)

- 10 to < 13 years (males and females 1.2 mg/dL)

- 13 to < 16 years (males 1.5 mg/dL and females 1.4 mg/dL)

- = 16 years (males 1.7 mg/dL and females 1.4 mg/dL)

- Bilirubin = 1.5 times upper limit of normal (ULN) for age

- SGPT (ALT) = 110 µ/L (for the purpose of this study, the ULN for SGPT is 45 µ/L)

- Serum albumin = 2 g/dL

- Patients with known bone marrow metastatic disease will be eligible for study but not evaluable for hematologic toxicity

- Patients must not be known to be refractory to red cell or platelet transfusion

- Patients with solid tumors without bone marrow involvement must meet the following criteria:

- Peripheral absolute neutrophil count = 1,000/µL

- Platelet count = 100,000/µL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)

- Hemoglobin = 8.0 g/dL (may receive RBC transfusions)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 3 months after completion of study therapy

- No uncontrolled infection

- No known type I or type II diabetes mellitus

- Able to comply with the safety monitoring requirements of the study, in the opinion of the investigator

- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to IMC-A12

- Fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study

- At least 7 days since prior and no concurrent hematopoietic growth factors

- Growth factors that support platelet or white cell number or function can only be administered for culture-proven bacteremia or invasive fungal infection

- At least 7 days since prior and no concurrent biologic antineoplastic agents

- At least 6 weeks since prior monoclonal antibodies

- At least 3 months since prior total body irradiation (TBI), craniospinal external radiotherapy (XRT), or = 50% radiotherapy to the pelvis

- At least 2 weeks since prior local XRT (small port)

- At least 6 weeks since other prior substantial bone marrow radiotherapy

- More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)

- More than 7 days since prior and no concurrent systemic corticosteroids

- Prior stem cell transplant or rescue allowed provided there has been no evidence of active graft-versus-host-disease within the past 2 months

- No prior monoclonal antibody therapy targeting the IGF-IR

- No concurrent chemotherapy, radiotherapy, or immunotherapy

- No concurrent anticancer agents

- No concurrent insulin or growth hormone therapy

- No other concurrent investigational drugs

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
cixutumumab
Given IV
Other:
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States COG Phase I Consortium Arcadia California

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 Toxicity tables will be constructed to summarize the observed incidence by severity and type of toxicity. Weekly during each course Yes
Primary MTD or recommended phase II dose MTD will be the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT). DLT is defined as any hematological and non-hematological toxicities that is possible, probably, or definitely attributed to IMC-A12. During course 1 Yes
Primary Pharmacokinetics of IMC-A12 At baseline, days 1, 8, 15, 22, and 28 of course 1, and days 15 and 28 of course 2 No
Secondary Response rate (complete or partial response) in patients with Ewing sarcoma/peripheral PNET Confidence intervals will be constructed according to the method of Chang and O'Brien to account for the two-stage design. Up to 30 days after completion of treatment No
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT01164163 - INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Phase 1
Completed NCT00985868 - AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors Phase 1
Terminated NCT00949117 - Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer Phase 2
Completed NCT00281944 - Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors Phase 1
Completed NCT00253474 - PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma Phase 1
Recruiting NCT00084695 - Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Phase 2
Completed NCT00053963 - FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Phase 1
Completed NCT00003070 - Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer Phase 3
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00016861 - Irinotecan in Treating Children With Refractory or Progressive Solid Tumors Phase 1
Completed NCT00003754 - Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers Phase 2
Completed NCT00004005 - Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin Phase 2
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Recruiting NCT00898794 - Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer N/A
Terminated NCT00429702 - Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy Phase 2
Completed NCT00387920 - Sunitinib in Treating Young Patients With Refractory Solid Tumors Phase 1
Completed NCT00459238 - Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants N/A
Completed NCT00138216 - Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Phase 1
Completed NCT00070473 - Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors Phase 1